We’re here for the entrepreneurs

April 18, 2017

Amgen Innovator Series: Scalable cell engineering via ultrasonic microfluidic vortex shedding

AmgenAprilRyan S. Pawell
CEO, Indee

Cell-derived gene therapies (CDGTs) – cell-based therapies requiring an intracellular delivery step – offer the opportunity to radically impact patient outcomes across several challenging disease areas. A potential limitation in the application and distribution of these therapies is their ability to be manufactured in a scalable and affordable manner.

Indee is working to address this problem by developing an intracellular delivery platform that scales up and out to meet the demands of the diseased patient populations by delivering functional macromolecules (DNA, RNA, endonucleases, etc.) to therapeutically­ relevant cell types (HSCs, iPSCs, T­Cells, etc.).

RyanRyan Pawell is an Eagle Scout, engineer, inventor and scientist turned biotech entrepreneur. He is an alumni of Y Combinator’s Winter 2017 cohort and recently submitted his PhD on biomicrofluidics. Ryan is a graduate the NSW Health Ignition Medical Program. He completed a BSci Mechanical Engineering at UC Santa Barbara while working with NuVasive and Inogen on medical device development. More recently, Ryan raised a meaningful amount of both private and venture financing to develop biomicrofluidic devices for scalable cellular engineering.

Upcoming Event

  • Reaction before action: new approaches to biomineralization-associated diseases

    12:30-13:30
    10/19/2017
    Daniel Laser, PhD CEO and Co-Founder, Applaud Medical RSVP Applaud Medical is a three-year-old company developing treatments for biomineralization-related diseases. Applaud's products use violent physical effects like cavitation and shock waves to achieve a therapeutic effect, while sparing non-targeted tissue through precise chemical targeting. Applaud's lead product, for low-invasiveness treatment of kidney stones, is currently in clinical trials in Gujarat, India. This seminar will cover technical aspects of combining chemical reactions with mechanical action in both Applaud's products and in a range of other drugs and devices, along with a brief discussion of key commercialization considerations for this uniquely promising product category. About Daniel Laser Daniel Laser is Chief Executive Officer and co-founder of Applaud Medical. Dan also founded Wave 80 Biosciences, a pioneer in detecting HIV during the high-transmission-risk earliest phase of infection, when the immune response is insufficiently advanced for antibody-based methods. He has served as board member or advisor to drug and device companies in fields ranging from autoimmune disease to ophthalmology to cancer. Dan got his start in the medical device field working on haptic feedback for telerobotic surgery systems. Dan holds a Ph.D. in mechanical engineering from Stanford University, where he was a Semiconductor Research Corporation Graduate Fellow. While at Stanford, he was also a MacArthur Affiliate at Stanford’s Center for International Security and Cooperation, developing mathematical models for protecting against threats involving weaponized pathogens.

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter